Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio
Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Related

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

 Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026

Vinge advises Dunlop Aircraft Tyres in connection with its issuance of USD 93 million senior secured bonds

 Vinge has advised Dunlop, in connection with its issuance of senior secured bonds in the amount of USD 93 million, under a total framework of USD 120 million.
January 08, 2026

Vinge advises Stockwik Förvaltning in conjunction with the acquisition of Labino

 Vinge has advised Stockwik Förvaltning in connection with its acquisition of Labino, a world-leading Swedish manufacturer of industrial UV light fixtures.
December 19, 2025